Literature DB >> 10940443

Executive dysfunction predicts nonresponse to fluoxetine in major depression.

J J Dunkin1, A F Leuchter, I A Cook, J E Kasl-Godley, M Abrams, S Rosenberg-Thompson.   

Abstract

BACKGROUND: Functional brain imaging studies of major depression have consistently revealed hypometabolism or hypoperfusion in specific regions of the prefrontal cortex and basal ganglia. Studies of cognitive functioning in major depression have suggested that some but not all subjects exhibit cognitive deficits that are consistent with frontal-subcortical dysfunction, although the reasons for this heterogeneity are unclear. In this study, we explored this heterogeneity among depressed subjects by examining the relationship between cognitive functioning and treatment outcome.
METHOD: Subjects with major depression were administered a complete neuropsychological test battery prior to treatment with fluoxetine.
RESULTS: There were no significant differences between responders and nonresponders to fluoxetine in terms of age, educational achievement, number of past episodes of depression, and estimated premorbid IQ. However, nonresponders performed significantly worse than responders on several pretreatment measures of executive functioning, after controlling for baseline group differences in depression severity. LIMITATIONS: The results are based on a small sample of primarily female subjects, resulting in low statistical power and less generalizability to samples of male subjects with depression.
CONCLUSIONS: The findings suggest that subtle prefrontal dysfunction in subjects with major depression may be predictive of poor response with particular medications. Assessment of the executive functions may play a particular role in pretreatment identification of subjects likely to respond to specific medications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940443     DOI: 10.1016/s0165-0327(99)00157-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  68 in total

Review 1.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review.

Authors:  Hannah R Snyder
Journal:  Psychol Bull       Date:  2012-05-28       Impact factor: 17.737

Review 3.  A Meta-Analysis of Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression.

Authors:  Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed
Journal:  Am J Geriatr Psychiatry       Date:  2015-05-21       Impact factor: 4.105

4.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

5.  Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study.

Authors:  Fadi T Maalouf; Giovanna Porta; Benedetto Vitiello; Graham Emslie; Taryn Mayes; Gregory Clarke; Karen D Wagner; Joan Rosenbaum Asarnow; Anthony Spirito; Martin Keller; Boris Birmaher; Neal Ryan; Wael Shamseddeen; Satish Iyengar; David Brent
Journal:  J Affect Disord       Date:  2012-01-30       Impact factor: 4.839

6.  Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings.

Authors:  Gerard E Bruder; James P Sedoruk; Jonathan W Stewart; Patrick J McGrath; Frederic M Quitkin; Craig E Tenke
Journal:  Biol Psychiatry       Date:  2007-12-03       Impact factor: 13.382

7.  Domain-specific impairment in cognitive control among remitted youth with a history of major depression.

Authors:  Amy T Peters; Rachel H Jacobs; Natania A Crane; Kelly A Ryan; Sara L Weisenbach; Olusola Ajilore; Melissa Lamar; Michelle T Kassel; Laura B Gabriel; Amy E West; Jon-Kar Zubieta; Scott A Langenecker
Journal:  Early Interv Psychiatry       Date:  2015-07-14       Impact factor: 2.732

8.  Testing the nanoparticle-allostatic cross-adaptation-sensitization model for homeopathic remedy effects.

Authors:  Iris R Bell; Mary Koithan; Audrey J Brooks
Journal:  Homeopathy       Date:  2013-01       Impact factor: 1.444

9.  Current Neural and Behavioral Dimensional Constructs across Mood Disorders.

Authors:  Scott A Langenecker; Rachel H Jacobs; Alessandra M Passarotti
Journal:  Curr Behav Neurosci Rep       Date:  2014-09-01

10.  Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.

Authors:  Andrew F Leuchter; Melinda Morgan; Ian A Cook; Jennifer Dunkin; Michelle Abrams; Elise Witte
Journal:  Psychopharmacology (Berl)       Date:  2004-07-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.